DermTech

Based in La Jolla, California, DermTech develops non-invasive genomic tests that utilize adhesive patches to collect skin samples for the precise detection of melanoma and other skin cancers. The publicly traded company processes these diagnostic samples in its CLIA-certified laboratory using quantitative PCR and gene expression analysis to significantly reduce the need for surgical biopsies. Operating with a workforce of approximately 90 employees, the firm transitioned to the public markets via a SPAC merger in September 2019, raising $143 million and subsequently reaching a peak market valuation of $1 billion. The organization's executive leadership and board of directors have included notable healthcare industry figures such as John Dobak, Burkhard Jansen, Kirk D. Malloy, and Mark C. Capone. DermTech was initially founded in 1999, with early leadership including founding chief financial officer Steven Kemper.